



Capra, V., Accomazzo, M. R., Rovati, G. E., Capra, V., Mauri, M., Guzzi, F., ... Mundell, S. J. (2017). Impaired thromboxane receptor dimerization reduces signaling efficiency: A potential mechanism for reduced platelet function in vivo. *Biochemical Pharmacology*, 124, 43-56.  
<https://doi.org/10.1016/j.bcp.2016.11.010>

Peer reviewed version

License (if available):  
CC BY-NC-ND

Link to published version (if available):  
[10.1016/j.bcp.2016.11.010](https://doi.org/10.1016/j.bcp.2016.11.010)

[Link to publication record in Explore Bristol Research](#)  
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at <https://www.sciencedirect.com/science/article/pii/S0006295216303975?via%3Dihub#f0010>. Please refer to any applicable terms of use of the publisher.

## University of Bristol - Explore Bristol Research

### General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:  
<http://www.bristol.ac.uk/pure/about/ebr-terms>

**Impaired Thromboxane Receptor Dimerization Reduces Signaling Efficiency: A  
Potential Mechanism For Reduced Platelet Function *In Vivo***

Valérie Capra<sup>a,b\*</sup>, Mario Mauri<sup>c\*</sup>, Francesca Guzzi<sup>c</sup>, Maria Rosa Accomazzo<sup>a</sup>, Pascale Gaussem<sup>d</sup>, Shaista P. Nisar<sup>e</sup>, Stuart J. Mundell<sup>e</sup>, Marco Parenti<sup>c</sup>, G. Enrico Rovati<sup>a</sup>

<sup>a</sup>From the Department of Pharmacological and Biomolecular Sciences and <sup>b</sup>Department of Health Science, University of Milan, Milano, Italy. E-mail addresses: [Valerie.Capra@unimi.it](mailto:Valerie.Capra@unimi.it), [Genrico.Rovati@unimi.it](mailto:Genrico.Rovati@unimi.it)

<sup>c</sup>Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. E-mail addresses: [mario.mauri@unimib.it](mailto:mario.mauri@unimib.it), [francesca.guzzi@unimib.it](mailto:francesca.guzzi@unimib.it), [marco.parenti@unimib.it](mailto:marco.parenti@unimib.it)

<sup>d</sup>Inserm UMR S765, Faculté de Pharmacie, Paris; Université Paris Descartes, and AP-HP, Hopital Européen Georges Pompidou, Service d'Hématologie Biologique, Paris, France. E-mail address: [pascale.gaussem@univ-paris5.fr](mailto:pascale.gaussem@univ-paris5.fr)

<sup>e</sup>School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK. E-mail addresses: [shaista.nisar@bristol.ac.uk](mailto:shaista.nisar@bristol.ac.uk), [s.j.mundell@bristol.ac.uk](mailto:s.j.mundell@bristol.ac.uk)

\* These two authors equally contributed to the paper

Corresponding author:

G.Enrico Rovati, Department of Pharmacological and Biomolecular Sciences,

University of Milan, Via Balzaretti 9, 20133 Milano, Italy Tel.: (+39) 0250319369;

E-mai: [Genrico.Rovati@unimi.it](mailto:Genrico.Rovati@unimi.it)

## **ABSTRACT**

Thromboxane A<sub>2</sub> is a potent mediator of inflammation and platelet aggregation exerting its effects through the activation of a G protein-coupled receptor (GPCR), termed TP. Although the existence of dimers/oligomers in Class A GPCRs is widely accepted, their functional significance still remains controversial. Recently, we have shown that TP $\square$  and TP $\square$  homo-/hetero-dimers interact through an interface of residues in trans-membrane domain 1 (TM1) whose disruption impairs dimer formation. Here, biochemical and pharmacological characterization of this dimer deficient mutant (DDM) in living cells indicates a significant impairment in its response to agonists. Interestingly, two single loss-of-function TP $\square$  variants, namely W29C and N42S recently identified in two heterozygous patients affected by bleeding disorders, match some of the residues mutated in our DDM. These two naturally occurring variants display a reduced potency to TP agonists and are characterized by impaired dimer formation in transfected HEK-293 cells. These findings provide evidences that lack of homo-dimer formation is a crucial process for reduced TP $\square$  function *in vivo*, and might represent one molecular mechanism through which platelet TP $\square$  receptor dysfunction affects the patient(s) carrying these mutations.

**Keywords:** G protein coupled receptors (GPCR); Thromboxane A<sub>2</sub>; Signal transduction; Receptor regulation; Platelets; Eicosanoid;

## 1. INTRODUCTION

The completion of the human genome project identified 7 transmembrane receptors, commonly referred to as G protein-coupled receptors (GPCRs), as the widest gene family [1]. Among the five different subfamilies, the Class A or rhodopsin-like GPCRs, to which the thromboxane A<sub>2</sub> receptor (TP) belongs, is the largest [2]. Members of this receptor family exert a wide variety of physiological processes with alterations in GPCR function contributing to the development of a number of pathological processes. Consequently, more than 30% of the current marketed drugs target GPCRs [3], with ongoing efforts to identify new molecules targeting the function of these proteins.

Membrane receptors from other families have long been known to form multimeric complexes, including members of the growth factor receptor family [4]. Conversely, for a long time GPCRs were considered to function as monomeric entities with their activation resulting from the stoichiometric binding of one receptor moiety to a single heterotrimeric G protein. Indeed, a number of biochemical and biophysical data are consistent with the ability of rhodopsin [5-7], or other GPCRs [8-10] to activate their cognate G proteins in a monomeric form. However, pharmacological data from various GPCRs are not compatible with such a model, and increasing evidence suggests that these receptors exist and function as oligomeric complexes of two or more protomers [11]. Although controversial until a few years ago, the formation of GPCR dimers/oligomers has now been demonstrated not only in ectopically transfected cells, but also in native tissues *in vivo* and even through the resolution of crystallized receptor structures [12]. In spite of these evidence and of the undisputed role of dimerization for Class C GPCRs [13, 14], the significance of dimerization remains controversial for the other classes of GPCRs [15] [16].

Thromboxane A<sub>2</sub> (TxA<sub>2</sub>), a product of the oxidative metabolism of arachidonic acid, is a potent mediator of inflammation, a stimulator of platelet activation and aggregation, and a

constrictor and mediator of proliferation of vascular and airway smooth muscle cells [17, 18]. In humans, the TP receptor is coded from a single gene that undergoes alternative splicing. This gives rise to two isoforms, termed TP $\alpha$  (343 residues) and TP $\beta$  (407 residues) which share identical N-terminal 328 amino acids and different C-terminal tails of 15 and 79 aminoacids, respectively [19]. The two isoforms primarily activate G<sub>q/11</sub> and G<sub>12/13</sub> heterotrimeric G proteins, although coupling to G<sub>s</sub>, G<sub>i</sub>, and G<sub>h</sub> has also been reported [19].

The TxA<sub>2</sub>/TP receptor exerts a key role in the cardiovascular system by triggering thrombus formation [20]. This has been well demonstrated through the identification of a number of patients suffering from hemostatic defects with impaired TP receptor function due to single amino acid substitutions [21-24]. TP function appears to be tightly regulated, with suggestions that the deleterious cardiovascular effects of TP $\alpha$  could be limited by heterodimerization with either the TP $\beta$  [25, 26] or prostacyclin IP receptor [27, 28], which have been shown to regulate TP $\alpha$  trafficking and G protein coupling.

Different artificial systems, such as solubilization in detergents [5, 9, 29], purification and refolding in detergent/lipid mixed micelles [10], or incorporation into phospholipid bilayer [6, 7], have been used to isolate GPCR monomers thus allowing the characterization of receptor monomer versus dimer pharmacology. Here, we directly compare in living cells the pharmacology and signaling of the homo-dimeric and monomeric forms of a Class A GPCR.

Recently, we have shown that TP $\alpha$  and TP $\beta$  homo-/hetero-dimers are characterized by contacts between hydrophobic residues in transmembrane domain 1 (TM1) of both protomers [26]. Indeed, TM1 and TM4/5 dimers, which appear more frequently in the crystals, are the most plausible dimeric models [30]. The disruption of this interface by alanine replacement of eight amino acids (Fig. 1) facing outward in dimerization-deficient mutants (DDMs) of one of the two TP isoforms is sufficient to drastically impair TP $\alpha$ -TP $\alpha$  hetero-dimerization and to significantly interfere with agonist-induced TP $\alpha$  endocytosis. Here, we demonstrate

that a panel of pharmacodynamically distinct agonists show reduced potencies but similar efficacies in the activation of the DDM with respect to wild type (WT) TP $\alpha$  homo-dimer. In addition, these agonists maintained identical binding affinities for both DDM and WT receptors, suggesting a similar active receptor conformation. Strikingly, we also show here that two single naturally occurring mutation in TM1, W29C and N42S, that are in close proximity to two of the residues mutated in our DDM (W29 and L43, respectively) display a reduced potency to agonists accompanied by an impaired dimer formation both in ectopically transfected HEK-293T cells and, at least partially, in platelet membranes from patients. These naturally occurring mutations are associated *in vitro* with reduced TP receptor-stimulated platelet activation and *in vivo* bleeding disorders [23, 24]. Overall, these data suggest the impairment of TP dimerization as one possible molecular mechanism leading to reduced platelet aggregation and secretion in response to TP activators *in vivo* thereby affecting patients carrying these mutations.

## 2. MATERIALS AND METHODS

### 2.1 Reagents

Cell-culture media and supplements, animal serum, antibiotics, Lipofectamine® 2000, Opti-MEM I and molecular biology reagents were purchased from Invitrogen (Carlsbad, CA). Inositol-free Dulbecco's modified Eagle's medium (DMEM) was from ICN Pharmaceuticals Inc. (Costa Mesa, CA). Ultima Gold™ was from PerkinElmer Life and Analytical Sciences (Boston, MA), as were [5,6-<sup>3</sup>H]SQ29,548 and myo-[2-<sup>3</sup>H]inositol. U46619 ([1R-[1 $\alpha$ ,4 $\alpha$ ,5 $\alpha$ (Z),6 $\alpha$ (1E,3S\*)]]-7-[6-(3-hydroxy-1-octenyl)-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid), I-BOP ([1S-[1 $\alpha$ ,2 $\alpha$ (Z),3 $\alpha$ (1E,3S\*),4 $\alpha$ ]]-7-[3-[3-hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid), 8-isoPGF<sub>2</sub> $\alpha$  (8-iso Prostaglandin F<sub>2</sub> $\alpha$ ), 8-isoPGE<sub>2</sub> (8-iso Prostaglandin E<sub>2</sub>), PTA<sub>2</sub> (Pinane TxA<sub>2</sub> - 9 $\alpha$ ,11 $\alpha$ -

(dimethyl)methylene-15S-hydroxy-11 $\beta$ -deoxy-11 $\beta$ -methylene-thromba-5Z,13E-dien-1-oic acid) and SQ29,548 ([1S-[1 $\beta$ ,2 $\beta$ (Z),3 $\beta$ ,4 $\beta$ ]]-7-[3-[[2-[(phenylamino)carbonyl]-hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) and Ramatroban (3R-[[[4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid) were from Cayman Chemical (Ann Arbor, MI). Anion exchange resin AG 1X-8 (formate form, 200–400 mesh) and Lowry dye-binding protein reagents were from Bio-Rad (Hercules, CA). All other reagents of the highest purity were available from Sigma-Aldrich (St. Louis, MO).

## 2.2 DNA constructs

The generation of human TP $\beta$  receptor WT, DDM, and W29C DNA constructs was described elsewhere [23, 26, 31]. TPtrunc was obtained using the site direct mutagenesis kit (statagene) following manufacturer's instructions. Briefly TPtrunc was obtained by the insertion of a stop codon at the Ser57 of receptor sequence (Ser57-Stop) using specific primers carrying the Ser57-Stop mutation (FW: 5'-GCGCGGCAGGGTGGTTAGCACACGCGCTCCTCC-3'; RW: 5'-GGAGGAGCGCGTGTGCTAACCACCCTGCCGCGC-3'). Mutated constructs was checked by sanger analysis.

The cDNA encoding for the G $\alpha_q$  was purchased from Missouri S&T cDNA Research Center (Rolla, MO, USA). Ultrapure plasmids for cell transfection were obtained using the QIAfilter Plasmid Kits (Qiagen, Hilden, Germany).

## 2.3 Cell culture and transient transfections

HEK293T host cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA). Cells were routinely grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin and 20 mM HEPES buffer pH 7.4, at 37°C in a humidified atmosphere of 95%

air and 5% CO<sub>2</sub>. For transfection, cells were seeded onto tissue culture dishes previously coated with 5 µg/ml poly-D-lysine, and transfected at 30–40% confluence with an optimized 2:1 Lipofectamine 2000/DNA ratio as described previously [32]. All assays were performed 48 hours after transfection. In co-transfection experiments with TP and G<sub>αq</sub>, plasmids were added in a 1:5 µg ratio, respectively.

## **2.4 Western immunoblotting**

Transfected cells were lysed in lysis buffer containing a protease inhibitor cocktail (Sigma-Aldrich). Equal amounts of proteins were resolved on SDS-PAGE (10% acrylamide) and electro-transferred to Hybond-P membrane (GE Healthcare-Amersham, Piscataway, NJ). Blots were incubated overnight at 4°C in TBST [10mM Tris-HCl buffer, pH 8.0, 150 mM NaCl, 0.1% (v/v) Tween 20] containing 5% (w/v) skimmed milk. After washing with TBST, membranes were incubated at 25°C for 2 h with anti-Myc antibody diluted in TBST-milk (Pierce, Rockford, IL). After washing in TBST, membranes were probed for 1.5 h at 25°C with horseradish peroxidase-conjugated goat anti-rabbit/mouse IgGs diluted in TBST-milk. Proteins were detected by chemiluminescence using the SuperSignal West Dura Extended Duration Substrate (Pierce) and visualized with Kodak Image Station 440 CF (Eastman Kodak Co., New Haven, CT). Band intensities were measured with the ‘gel analyzer’ ImageJ<sup>®</sup> plugin.

Platelets were probed using Abcam ab85544 a rabbit polyclonal antibody against the carboxyl-terminal of the human TP receptor as previously described [23].

## **2.5 Radioligand binding and total inositol phosphate assays**

Receptor expression and functional activity were monitored 48 hours after transfection. Ligand binding characteristics were determined on confluent adherent cells performing a mixed-type protocol [33] with the specific receptor antagonist [<sup>3</sup>H]SQ29,548 (48 Ci/mmol)



as previously described [31, 32, 34]. Briefly, heterologous competition studies involved concentrations of the indicated unlabeled ligands ranging from 0.1 nM to 30  $\mu$ M against 1 nM [<sup>3</sup>H]SQ29,54. After 30 min incubation at 25°C, reactions were stopped by medium aspiration, and cells were washed with ice-cold PBS containing 0.2% (w/v) BSA and lysed in 0.5 N NaOH. Radioactivity was measured by liquid scintillation counting. Binding data were analyzed as described in Data and Statistical Analysis. Quantitation of the total labeled IP accumulation was performed using a conventional gravity flow column chromatography, as described previously [31, 32, 34]. Briefly, on day before assay, cells were labeled with 0.5  $\mu$ Ci [myo-2-<sup>3</sup>H]inositol (17 Ci/mmol) for 18-20 hours in serum- and inositol-free DMEM containing 20 mM HEPES buffer, pH 7.4, and 0.5% (w/v) Albumax I. On day of assay, medium was replaced with serum-and inositol-free DMEM containing 25 mM LiCl and cells stimulated for 30 min with the indicated agonists. After medium removal, cells were lysed with 10 mM formic acid and lysates applied onto an anion exchange AG 1X-8 column, formate form, 200-400 mesh. The total IP fraction was then eluted with 2 M ammonium formate/formic acid buffer at pH 5 and radioactivity determined by liquid scintillation counting.

## **2.6 Acceptor photobleaching Fluorescence Resonance Energy Transfer (FRET)**

FRET measurements were performed with the laser-induced acceptor bleaching method previously reported [26, 35]. This type of analysis employing antibodies on living cells instead of fused fluorescent reporters to label the FRET pair offers the unique advantage over conventional FRET of only assaying surface receptors. Briefly, following *in vivo* exposure with anti-tag antibodies, cells were fixed in 4% (w/v) p-formaldehyde, and stained with Alexa Fluor 488- (donor fluorochrome) or 555 (acceptor fluorochrome)-conjugated secondary antibodies. Three images were captured before bleaching in the 488 and 555 nm channels using the line-by-line sequential mode without any averaging steps to reduce basal

bleaching. Bleaching of the acceptor was performed within a region of interest (ROI) using 30 pulses of the 555 nm laser line at 100% intensity (each pulse 1.28  $\mu$ sec/pixel). After bleaching seven images were acquired in the same channels to obtain a full curve for analysis. The number of bleaching steps was held constant throughout each experiment. FRET was quantified by measuring the average intensities of ROIs in the donor and acceptor fluorochrome channels before and after bleaching using the ImageJ software (<http://rsbweb.nih.gov/ij/>). To determine any change of fluorescence intensities not due to FRET occurring during the measurements, a distinct membrane ‘sentinel’ ROI of approximately the same size of the bleached ROI was measured in parallel, and all the results were normalized according to the background bleaching recorded in this sentinel ROI. Proper controls were performed to verify that no artifacts were generated in the emission spectra throughout the experimental setup due to sample overheating. Forty measurements from four different transfections were performed for each experimental condition.

## **2.7 Data and statistical analysis**

All results are presented as means  $\pm$  S.E. When indicated, ANOVA followed by post-hoc test for multiple comparisons was performed. Data from radioligand binding were evaluated by a nonlinear, least-squares curve-fitting procedure using GraphPad Prism version 5, implemented with the n-ligand m-binding site model, as described in the LIGAND computer program [36]. Concentration-response curves were evaluated using Prism 5, that uses the four-parameter logistic model as described in the ALLFIT program [37]. Parameter errors are all expressed as percentage coefficients of variation (%CV) and calculated by simultaneous analysis of at least three independent experiments performed in duplicate or triplicate. All parameter comparisons have been performed based on the F test for model comparison as implemented in GraphPad Prism. All curves shown are generated by computer fitting.

### 3. RESULTS

#### 3.1 Antagonist Binding and Receptor Expression

To allow a proper comparison of receptor responses, transfection conditions were adjusted to ensure comparable levels of ectopic expression of WT and DDM (I25A, W29A, C35A, V36A, L39A, L43A, L44A, S47A mutant) of human TP $\alpha$  receptors in HEK293T cells in a range between 0.8-1.3 pmol/mg protein (Table 1). As expected, mock transfected cells showed no detectable binding to [<sup>3</sup>H]-SQ29,548, whereas analysis of binding curves of cells transiently transfected with WT TP $\alpha$  displayed a monophasic behavior corresponding to a single-site model by computer fitting (Fig. 2A), with binding parameters as previously reported [31, 32, 34]. The TP $\alpha$ -DDM displayed a binding affinity not statistically different from the corresponding WT receptor (Table 1). These results strongly indicate that DDM, is trafficked to the cell surface (Fig. 2B), can be expressed at physiological relevant levels and exhibits an overall conformation and folding not significantly different from that of WT.

#### 3.2 Effect of TM1 mutations on homo-dimerization of TP $\alpha$ receptor

We previously reported that WT TP $\alpha$  and TP $\alpha$  form hetero-dimers through contacts between hydrophobic residues of TM1 with mutations in the TM1 stretch impairing TP $\alpha$ -TP $\alpha$  association regardless of which TP member of the co-transfected pair contains the mutated residues [26]. To confirm that the TP $\alpha$  DDM is impaired in homo-dimer formation, we co-expressed WT and DDM mutant TP $\alpha$  tagged with an N-terminal myc epitope in HEK293T cells. Western blotting revealed distinct bands migrating on SDS-PAGE at the relative molecular masses (*M<sub>r</sub>*) predicted for monomeric and dimeric receptors for WT transfectants (Fig. 2C). Interestingly, unlike the WT most of the DDM exists as a monomer. There was a significant reduction of the density of the dimeric band in DDM

accompanied by increased intensity of monomeric bands referred to as glycosylated and non-glycosylated TP monomers as previously reported [25] ( $p < 0.001$ , Fig. 3B).

To obtain direct evidence that mutations in the TM1 interface of DDM impair TP $\alpha$  dimerization, we performed FRET analysis using the laser-induced acceptor photobleaching method [35]. In this type of analysis fluorescence emission by a donor fluorochrome is quenched due to direct transfer of excitation energy to an acceptor fluorochrome. Upon laser-induced acceptor fluorochrome bleaching this FRET is blunted and the donor signal is de-quenched. Accordingly, HEK293T cells co-transfected with different TP $\alpha$  pairs, tagged with HA and c-myc epitopes, were *in vivo* labeled with their corresponding anti-tag antibodies, fixed, subjected to indirect immunofluorescence and then imaged by laser scanning confocal microscopy. Figure 3C demonstrates our approach. Note that an increase of fluorescence signal emitted by the donor fluorochrome resulting from de-quenching (i.e. FRET efficiency) is only present in analyzed cells co-expressing the WT TP $\alpha$  pair, whereas no increase occurs in the DDM expressing cells.

To further characterize this phenomenon we repeated the experiments by transfecting cells with different levels of the TP $\alpha$  DNA (500, 5 and 0.5 ng) (Fig. 3D). Even at the highest levels of DDM receptor expression we could still not detect any interaction between receptor monomers although we could clearly visualize both tagged versions of the receptor at the cell surface (Fig. 2B). These results suggest that homo-dimerization of TP $\alpha$  within a large range of expression levels, including physiological ones (corresponding to the intermediate level [38], is strongly destabilized in the receptor bearing TM1 mutations.

### **3.3 Basal Activity of DDM receptor in the presence of overexpression of G $\alpha_q$**

A key feature of the TP receptor is a lack of constitutive activity (CA), even following increased expression of receptor, G $\alpha_q$ , or a combination of both [31, 34]. To further assess the pharmacological characteristics of the DDM receptor, its basal activity was compared

with that of the WT by assaying total IP production in the absence of agonist stimulation (Fig. 4). These experiments were also repeated in the presence of G $\alpha_q$  overexpression to try and promote CA at these receptors. In the mock condition, a 5-fold overexpression of G $\alpha_q$  induced an increase of total IP production (about 50% compared to no G $\alpha_q$ , Fig. 4), likely due to a general increase in this G protein as previously reported [34]. Co-expression of either the WT or DDM failed to further enhance total IP production. These results show that the DDM, like the WT and other TP receptor mutants tested thus far, does not show any appreciable CA [31, 32, 34].

### 3.4 Pharmacological characterization of the DDM functional activity

To fully characterize DDM activity, IP accumulation was evaluated in HEK293T cells transiently expressing WT or DDM in response to a series of pharmacodynamically different TP agonists, including the full agonists U46619 and I-BOP and the partial agonists 8-iso-PGF $_{2\alpha}$  and 8-isoPGE $_2$  (Fig. 5A, B). Computer-assisted analysis of concentration-response curves showed that EC $_{50}$  values for the different agonists at DDM were significantly shifted rightward as compared to WT ( $p < 0.01$ ; Table 2). 8-iso-PGF $_{2\alpha}$  and 8-isoPGE $_2$  activated the DDM and the WT with equal efficacies, in accordance with their pharmacodynamic profiles as partial agonists (Fig. 5A, B).

We also assessed the ability of the TP receptor antagonist SQ29,549 and the structurally unrelated TP and DP $_2$  antagonist ramatroban, to inhibit agonist (U46619 (1  $\mu$ M)-induced IP production by WT and DDM receptors ; Fig. 5C, D). Both antagonist inhibition curves at the DDM were significantly ( $p < 0.01$ ) leftward shifted with IC $_{50}$  values around 5-6 fold lower than the WT (IC $_{50}$  = 254 nM  $\pm$  66 %CV and 144  $\pm$  29 %CV for SQ29,548 and ramatroban, respectively, for WT vs. 45 nM  $\pm$  61 %CV and 29  $\pm$  56 %CV for SQ29,548 and ramatroban, respectively, for DDM). This apparent increase in antagonist potencies is likely a consequence the reduced potency of U46619 to activate DDM. Collectively, these data

indicate that the DDM form of TP□ less efficiently responds to agonist activation across a panel of compounds endowed with different intrinsic activities than the WT homo-dimeric form.

To confirm that the pharmacological profile of our artificial DDM is not due exclusively to the presence of the eight mutations in TM1, we co-transfected the WT TP receptor with a truncated form of TP coding only for the N terminal and TM1 regions (TPtrunc), an approach previously shown to destabilize the quaternary structure and the interaction interfaces of rhodopsin [39]. While TPtrunc alone was pharmacologically silent, co-transfection with the WT TP receptor reduced receptor function (Fig. 6A). Close examination of dose response curves revealed that WT TP receptor plus TPtrunc produced a receptor profile similar to DDM with potencies ( $EC_{50} = 84.8 \text{ nM} \pm 50 \%CV$  and  $111 \text{ nM} \pm 72 \%CV$ , respectively) and efficacies not statistically different. Notably, TPtrunc is expressed at cellular surface and laser-induced acceptor bleaching FRET demonstrated that it is able to dimerize with WT TP receptor (Fig. 6B). Thus, we can assume that the presence of an excess (1:10) of TPtrunc interfere with the WT-WT TP dimer formation, forcing WT TP receptor into a monomeric form. This, in turn, suggests that the pharmacological profile observed for the DDM might indeed be due to its monomeric state and not to merely the presence of mutations. It is likely that TPtrunc interferes with the quaternary structure of the homo-dimer, but do not necessarily block dimerization completely.

Transfection of a mutated form of the TPtrunc (carrying the same eight mutations as the DDM, TPtrunc TM1) with the WT TP receptor (Fig. 6A) resulted in concentration response curve identical to that of WT TP alone ( $EC_{50} = 23.2 \text{ nM} \pm 27 \%CV$  and  $35.6 \text{ nM} \pm 31 \%CV$ , respectively) demonstrating the specificity of the functional interference exerted by the truncated form of the receptor on TP dimers/oligomers and the importance of these eight amino acids in TM1 to WT TP receptor interaction.

### 3.5 Ligand binding profile of the DDM receptor

The ligand binding capacities of the WT and DDM receptors transiently expressed in HEK-293T cells were also tested to assess whether the ligand binding pocket and/or the active receptor conformation was affected by mutations. Heterologous competition curves performed with [<sup>3</sup>H]-SQ29,548 and several unlabeled agonists revealed unchanged affinities between both WT and DDM receptor constructs and an entire panel of compounds, including the two partial agonists 8-iso-PGF<sub>2</sub>α and 8-isoPGE<sub>2</sub> (Fig. 7A, B and Table 3). In addition to SQ29,548 (Table 1), also the structurally unrelated TP antagonist, PTA2 (Fig. 7C and D) did not show any difference in binding affinities between receptors ( $K_i = 3.6 \mu\text{M} \pm 68 \text{ \%CV}$  and  $K_i = 2.4 \mu\text{M} \pm 67 \text{ \%CV}$  for WT and DDM, respectively). These data, therefore, are consistent with similar agonist-induced receptor conformations and G protein coupling for both WT and DDM, suggesting that the difference in signaling efficiency might be due to a difference in G protein activation, rather than to a difference in receptor conformational states.

### 3.6 Impact of W29C and N42S mutations on dimerization and pharmacology of TP receptor

As mentioned above a patient heterozygous for the TP receptor variant W29C with impaired platelet response to TP receptor agonists has been previously identified [23]. In this study in HEK293T U46619 was demonstrated to be less potent at the W29C variant versus WT in inducing a rise of cytosolic free Ca<sup>2+</sup>, although the molecular mechanisms underlying this difference were not fully elucidated [23]. Importantly W29 is one of the eight residues mutated in our DDM [26] (Fig. 1). In order to study the impact of the single W29C mutation on dimerization of TP receptor, the endogenously expressed receptor in platelets was detected with an antibody directed against the carboxyl-terminal of human TP receptor. The TP receptor can be found in monomeric, dimeric and higher oligomeric forms in human platelets

from healthy donors (Fig. 8A, HD) [25]. Platelets from the W29C patient show only a modest reduction of the dimeric TP form (Fig. 8A, W29C), although quantification over multiple experiments seems to suggest a decrease of both dimeric and oligomeric forms (Fig. 8B) of receptor, which, however, did not reach statistical significance. These results were not totally unexpected, considering that the patient is heterozygous for the W29C mutation [23], and therefore may still be able to express a substantial amount of dimeric WT TP. To further investigate the functional significance of the W29C mutation, we again used laser-induced acceptor bleaching FRET methodology outlined above on transfected HEK 293T cells. Intriguingly there was no recovery of donor fluorescence due to a lack of energy transfer in cells overexpressing the WT-W29C pair ( $103\% \pm 0.8$  SE, Fig. 9A and B), suggesting minimal proximity and hence less dimerization between donor/acceptor proteins. Similar data were also obtained when we tested another naturally occurring mutation, N42S [24] with minimal evident energy transfer in our FRET studies (Fig 9B). It should be noted that this residue is just one upstream of the L43 and L44 residues mutated in our DDM (Fig. 1), a difference that might be due to the fact that we do not have a crystal structure of our receptor, but only an homology model [26]. Collectively, these results strongly suggest that TP dimerization is impaired with W29C or the N42S receptor variant, in striking agreement with the behavior of our artificial DDM.

We therefore further investigated the pharmacological profile of the W29C natural variant in functional assays (Fig. 9C). Concentration-response curves of all agonists for W29C were significantly shifted rightward as compared to WT, with calculated potencies ( $EC_{50} = 159$  nM  $\pm 21$  %CV and  $63 \pm 9$  %CV for U46619 and I-BOP, and  $EC_{50} = 1896$  nM  $\pm 37$  %CV and  $43280 \pm 56$  %CV for 8-iso-PGE<sub>2</sub> and 8-isoPGF<sub>2</sub>, respectively) consistent with those of the artificial DDM (Table 2). Interestingly, the pharmacological profile of the naturally occurring W29C mutant exactly matches that of the artificial DDM. Additionally, 8-iso-PGF<sub>2</sub> and 8-



isoPGE<sub>2</sub> also confirmed their pharmacodynamic profile as partial agonists activating the W29C variant with equal efficacies ( $E_{max} = 3.2 \pm 5 \%CV$  and  $3.6 \pm 16 \%CV$ , respectively). The antagonists SQ29,548 and ramatroban specifically inhibited U46619-induced total IP production by W29C with results not statistically different from DDM (data not shown).

#### **4. DISCUSSION**

Despite the intense effort devoted to demonstrate the mechanism(s) by which GPCRs form complexes with each other, the physiological relevance of this phenomenon still remains elusive [11, 15] [16]. Hetero-dimerization has been shown to be an absolute requirement for the activity of some Class C GPCRs [13, 14] and the cell-surface delivery of other GPCRs [40, 41]. The process can also be regarded as a way of creating a receptor complex endowed with unique signaling features in response to the binding of specific ligands [42, 43]. A more difficult point to characterize is the role of receptor homo-dimerization in terms of receptor activation and function. In order to address this question we characterized the pharmacological activity of the human TP receptor, containing either artificial (DDM TP) [26] or naturally occurring (W29C and N42S) [23, 24] mutations in TM1, impaired in its ability to spontaneously form receptor dimers.

The main key finding of the present study comes from the detailed pharmacological characterization of the DDM TP receptor using a combination of antagonists and full and partial agonists in living cells. Unlike the WT receptor which spontaneously forms homo-dimers at physiological expression levels, DDM, which is significantly impaired in its ability to form dimers, displays a significant reduction in agonist potency in comparison to the WT. Beyond a reduction in agonist potency, the WT and DDM receptors have indistinguishable overall and active conformations as assessed by antagonist and agonist ligand-binding studies and possess similar abilities to bind and induce G<sub>q</sub>-mediated signaling. Thus, TM1 appears to

be an important region contributing to the normal function of the TP $\alpha$  receptor *in vitro*. To support these findings two recent studies examining naturally occurring variants in the TP $\alpha$  receptor, W29C and N42S identified in two patients with bleeding disorders, demonstrated that platelets from these patients exhibited a decrease in TP receptor-stimulated activation. We now demonstrate that both W29C and N42S TP $\alpha$  receptor variants are impaired in their ability to dimerize in a recombinant system, and with a partial reduction also apparent in platelets from these patients. Strikingly, one of these naturally occurring mutations (W29C) exactly matches, and the other (N42S) is just one residue upstream of two out of the eight residues mutated in our artificial DDM. Thus, we suggest that a single mutation in TM1 might be sufficient to impair homo-dimer formation, and may in part be responsible for the observed decrease in TP receptor functionality observed *in vivo*.

Although DDM is expressed at the cell surface at physiologically relevant levels it is drastically impaired in its tendency to form homo-dimers over a range of different expression levels, as demonstrated by western blotting and acceptor photobleaching FRET analysis. Ligand-binding studies with the TP receptor antagonist SQ29,548 confirm normal protein folding, and suggest a conserved overall protein conformation, as also previously postulated by molecular dynamic simulations [26].

In functional assays DDM signaling was significantly impaired versus WT with a significant rightward shift in agonist-potency across a panel of full and partial TP receptor agonists. In agreement with this loss of agonist activity, two structurally different antagonists demonstrated an apparent increase in their potency. Most importantly, despite their reduced potency in promoting DDM activation, all the ligands investigated retained their respective pharmacological profiles as either full or partial agonists. In addition, the basal activity of DDM is similar to that of WT and not affected by increased expression of its cognate G protein, a further validation of TP ‘resistance’ to CA [31, 32, 34].

Importantly, co-transfection of the WT TP receptor with a truncated form of TP coding only for the N terminal and TM1 regions produced a pharmacological profile similar to that of the DDM. Because TPtrunc is able to dimerize with WT receptor, its co-expression very likely impairs WT-WT TP dimer formation, forcing TP receptor into a monomeric form. This, in turn, suggests that the monomeric form of TP, as for many other GPCRs, is able to signal, and that the pharmacological profile observed for the DDM might indeed be due to its monomeric state and not to merely the presence of mutations.

In addition, the phenotype described for this ‘artificial’ DDM matches the phenotypes of the W29C and N42S TP $\square$  natural variants [23, 24]. In these studies we suggested that reduced TP receptor surface expression seen in the W29C patient reduced TP receptor-stimulated platelet aggregation. We now speculate that in addition to this reduction in surface expression, since both the W29C and N42S are impaired in the dimerization with WT, the heterozygous patients may also display a shift in the normal equilibrium from TP $\square$  homodimers to monomers with a consequent overall decrease in agonist potency. Western blotting of patient platelets TP $\square$  reveals receptor in monomeric, dimeric, and higher-order oligomeric forms in agreement with previously published results [25]. These blots suggested that there maybe a modest reduction in TP $\square$  oligomer although it should be noted that both patients are heterozygous for each variant and therefore will also express WT TP receptor. The presence of WT TP receptor is likely to mask our ability to see a statistically significant reduction in dimer formation. Intriguingly, each of these variants shows comparable levels of maximal receptor responsiveness to agonists when compared to WT, but have reduced potency in second messenger production [23, 24], as it is the case for the artificial DDM. It is therefore tempting to speculate that the impairment in dimer formation might represent a crucial molecular mechanism of the decreased platelet response to TP agonists *in vivo*.

In an attempt to clarify whether the change in agonist potency might arise from a change in the ligand-binding pocket and/or in an allosteric effect within the protomers of the TP $\square$  homo-dimer [44], we analyzed the agonist binding profile of a series of compounds endowed with different intrinsic activities. All the tested agonists displayed equal binding affinities for the DDM and WT receptors, thus indicating that the agonist-induced active state of the monomeric and dimeric proteins are similar, and supporting the absence of any allosteric modulation across protomers of the TP $\square$  homo-dimer at the level of the binding pocket. Notably, the DDM retains high affinity agonist binding that is indicative of a normal coupling with the cognate G proteins. Thus, differences able to explain a reduced potency of agonists in DDM activation must be sought downstream of the TP receptor itself, likely at the G protein level.

Collectively, all these observations strongly support the notion that reduced agonist potencies demonstrated by the DDM in second messenger production do not arise from a change in the receptor state, i.e. by a variation in agonist-induced conformation, or in the receptor ability to recognize pharmacodynamically different agonists or in its ability to interact with G proteins. Rather, these data are suggestive of a reduced signaling strength, likely due to a reduced efficiency in G protein activation. While we recognize that we cannot completely rule out the possibility that the differences observed in our DDM might depend upon the presence of the mutations alone, the fact that a single mutation (W29C or N42S) or dimerization with a truncated and silent form of the receptor closely match the pharmacology of our DDM, convincingly indicates that the particular pharmacological profile observed with our TP mutants may be the result of an impairment of dimer/oligomer formation.

In respect to this, contrasting data are emerging on G protein activation by different dimeric GPCRs. Some data support a model of a higher efficiency of G protein activation in dimers/oligomers [29, 45, 46], whilst others demonstrate a similar degree of activation [6, 7],

or even a reduced G protein coupling efficiency by dimeric ensembles [9, 10]. While it is possible that different receptors might simply behave differently from another, it is also true that the same receptor seems to behave differently in different experimental conditions as shown with rhodopsin isolated by filtration techniques [29] versus expression in a phospholipid bilayer [7]. To our knowledge, our functional results are the first to be obtained with a dimeric and a monomeric form of a Class A GPCR expressed in living cells that is not artificially purified/reconstituted. More data on other receptor systems will certainly come in the near future to clarify this issue, as it has been recently the case for the glucagon-like peptide-1 receptor, where homo-dimer formation seems important for the control of signal bias [47].

Finally, while the stoichiometry of the receptor-G protein unit still remains an open question, a number of studies favor a 2:1 stoichiometry, corroborating the hetero-pentameric structure of two protomers binding one heterotrimeric G protein [46, 48-51]. A number of biochemical studies suggest the involvement of several distinct G protein regions in receptor interaction [52], both on the  $\beta$  [53, 54], as well as on the  $\beta$ -subunit [55, 56]. While the C-terminal sites on the  $\beta$ -subunit have been confirmed by crystallization to interact with opsin/metarhodopsin [57] and  $\beta_2$ -AR [58], unexpectedly, no direct interaction between  $\beta_2$ -AR and  $G\beta$ - or  $G\gamma$ -subunits have been detected [58]. Indeed biochemical studies suggest that  $\beta_2$ -AR exists as a dimer in living cells [59] and that the C-terminal of  $G\alpha$  and of  $G\gamma$  are further apart in the G protein heterotrimer than the width of a monomeric GPCR [60]. In addition, the 2:1 stoichiometry is consistent with multiple contact sites of the G protein with two different protomers [61, 62] whereas the heterotrimer appears necessary for efficient coupling to a GPCR [63]. In light of our data and of this ‘double docking’ model described above we can speculate that, when a secondary site of contact is available due to the presence of a homo-dimer, a stronger coupling with the cognate G protein is favored, hence more

efficient signaling is then possible. Indeed, the presence of transducin has been shown to stabilize the dimeric conformation of rhodopsin, while the presence of synthetic peptides that disrupt rhodopsin dimerization, similar to our truncated TP receptor construct, inhibited such stabilization [39].

In conclusion, our data propose that TP $\alpha$  receptor dimer formation favors a more efficient signaling complex, increasing agonist potency. This augmented ability maybe as the result of a more efficient G protein activation. Given that TP monomers and homo-dimers are, presumably, in equilibrium at steady state [64, 65], it is likely that when a single TP $\alpha$  protomer makes a complex with a TP $\alpha$  [25, 26] or IP protomer [27] there would be a shift in the equilibrium from TP $\alpha$  homo-dimers to monomers with a consequent overall decrease in agonist potency, which may be important in thrombosis-related diseases. In this respect, the impairment of W29C and N42S to form dimers with WT receptor may represent one molecular mechanism through which platelet TP receptor dysfunction affects the patient(s) carrying these mutations.

### **Acknowledgements**

The authors would like to acknowledge Prof. Francesca Fanelli for drawing of Figure 1.

This work was supported in part by a grant from Regione Lombardia (SAL-02) and from Fondazione Banca del Monte di Lombardia (to G.E.R.) - SJM is a Senior Research Fellow of the British Heart Foundation.

**Conflict of interest Statement:** None declared

## 5. REFERENCE

- [1] R.J. Lefkowitz, Seven transmembrane receptors: something old, something new, *Acta Physiol (Oxf)* 190(1) (2007) 9-19.
- [2] R. Fredriksson, M.C. Lagerstrom, L.G. Lundin, H.B. Schioth, The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints, *Mol Pharmacol* 63(6) (2003) 1256-72.
- [3] C.B. Brink, B.H. Harvey, J. Bodenstein, D.P. Venter, D.W. Oliver, Recent advances in drug action and therapeutics: relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology, *Br J Clin Pharmacol* 57(4) (2004) 373-87.
- [4] C.H. Heldin, Dimerization of cell surface receptors in signal transduction, *Cell* 80(2) (1995) 213-23.
- [5] O.P. Ernst, V. Gramse, M. Kolbe, K.P. Hofmann, M. Heck, Monomeric G protein-coupled receptor rhodopsin in solution activates its G protein transducin at the diffusion limit, *Proc Natl Acad Sci U S A* 104(26) (2007) 10859-64.
- [6] T.H. Bayburt, A.J. Leitz, G. Xie, D.D. Oprian, S.G. Sligar, Transducin activation by nanoscale lipid bilayers containing one and two rhodopsins, *J Biol Chem* 282(20) (2007) 14875-81.
- [7] M.R. Whorton, B. Jastrzebska, P.S. Park, D. Fotiadis, A. Engel, K. Palczewski, R.K. Sunahara, Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer, *J Biol Chem* 283(7) (2008) 4387-94.
- [8] M.R. Whorton, M.P. Bokoch, S.G. Rasmussen, B. Huang, R.N. Zare, B. Kobilka, R.K. Sunahara, A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein, *Proc Natl Acad Sci U S A* 104(18) (2007) 7682-7.

- [9] J.F. White, J. Grodnitzky, J.M. Louis, L.B. Trinh, J. Shiloach, J. Gutierrez, J.K. Northup, R. Grisshammer, Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction, *Proc Natl Acad Sci U S A* 104(29) (2007) 12199-204.
- [10] L. Arcemisbehere, T. Sen, L. Boudier, M.N. Balestre, G. Gaibelet, E. Detouillon, H. Orcel, C. Mendre, R. Rahmeh, S. Granier, C. Vives, F. Fieschi, M. Damian, T. Durroux, J.L. Baneres, B. Mouillac, Leukotriene BLT2 receptor monomers activate the G(i2) GTP-binding protein more efficiently than dimers, *J Biol Chem* 285(9) (2010) 6337-47.
- [11] S. Ferre, V. Casado, L.A. Devi, M. Filizola, R. Jockers, M.J. Lohse, G. Milligan, J.P. Pin, X. Guitart, G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives, *Pharmacol Rev* 66(2) (2014) 413-34.
- [12] V. Katritch, V. Cherezov, R.C. Stevens, Structure-function of the G protein-coupled receptor superfamily, *Annu Rev Pharmacol Toxicol* 53 (2013) 531-56.
- [13] J.H. White, A. Wise, M.J. Main, A. Green, N.J. Fraser, G.H. Disney, A.A. Barnes, P. Emson, S.M. Foord, F.H. Marshall, Heterodimerization is required for the formation of a functional GABA(B) receptor, *Nature* 396(6712) (1998) 679-82.
- [14] J. Kniazeff, L. Prezeau, P. Rondard, J.P. Pin, C. Goudet, Dimers and beyond: The functional puzzles of class C GPCRs, *Pharmacol Ther* 130(1) (2011) 9-25.
- [15] G. Milligan, The Prevalence, Maintenance and Relevance of GPCR Oligomerization, *Mol Pharmacol* (2013).
- [16] N.A. Lambert, J.A. Javitch, CrossTalk opposing view: Weighing the evidence for class A GPCR dimers, the jury is still out, *J Physiol* 592(Pt 12) (2014) 2443-5.
- [17] S. Narumiya, Y. Sugimoto, F. Ushikubi, Prostanoid receptors: structures, properties, and functions., *Physiological Reviews* 79(4) (1999) 1193-226.



- [18] A.N. Hata, R.M. Breyer, Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation, *Pharmacol Ther* 103(2) (2004) 147-66.
- [19] D.F. Woodward, R.L. Jones, S. Narumiya, International Union of Basic and Clinical Pharmacology. LXXXIII: Classification of Prostanoid Receptors, Updating 15 Years of Progress, *Pharmacol Rev* (2011).
- [20] V. Capra, M. Back, S.S. Barbieri, M. Camera, E. Tremoli, G.E. Rovati, Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke, *Med Res Rev* 33(2) (2013) 364-438.
- [21] T. Hirata, A. Kakizuka, F. Ushikubi, I. Fuse, M. Okuma, S. Narumiya, Arg60 to Leu mutation of the human thromboxane A<sub>2</sub> receptor in a dominantly inherited bleeding disorder, *Journal of Clinical Investigation* 94(4) (1994) 1662-7.
- [22] A.D. Mumford, B.B. Dawood, M.E. Daly, S.L. Murden, M.D. Williams, M.B. Protsy, J.C. Spalton, M. Wheatley, S.J. Mundell, S.P. Watson, A novel thromboxane A<sub>2</sub> receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis, *Blood* 115(2) (2010) 363-9.
- [23] A. Mumford, S. Nisar, L. Darnige, M. Jones, C. Bachelot-Loza, S. Gandrille, F. Zinzindoue, A.M. Fischer, S. Mundell, P. Gaussem, Platelet dysfunction associated with the novel Trp29Cys thromboxane A<sub>2</sub> receptor variant, *J Thromb Haemost* 11(3) (2012) 547-54.
- [24] S.P. Nisar, M. Lordkipanidze, M.L. Jones, B. Dawood, S. Murden, M.R. Cunningham, A.D. Mumford, J.T. Wilde, S.P. Watson, S.J. Mundell, G.C. Lowe, U.K.G.s.g. on behalf of the, A novel thromboxane A<sub>2</sub> receptor N42S variant results in reduced surface expression and platelet dysfunction, *Thromb Haemost* 111(5) (2014) [Epub ahead of print].
- [25] G. Laroche, M.C. Lepine, C. Theriault, P. Giguere, V. Giguere, M.A. Gallant, A. de Brum-Fernandes, J.L. Parent, Oligomerization of the alpha and beta isoforms of the

thromboxane A<sub>2</sub> receptor: relevance to receptor signaling and endocytosis, *Cell Signal* 17(11) (2005) 1373-83.

[26] F. Fanelli, M. Mauri, V. Capra, F. Raimondi, F. Guzzi, M. Ambrosio, G.E. Rovati, M. Parenti, Light on the structure of thromboxane A<sub>2</sub> receptor heterodimers, *Cell Mol Life Sci* 68(18) (2011) 3109-3120.

[27] S.J. Wilson, A.M. Roche, E. Kostetskaia, E.M. Smyth, Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation, *J Biol Chem* 279(51) (2004) 53036-47.

[28] S.J. Wilson, J.K. Dowling, L. Zhao, E. Carnish, E.M. Smyth, Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization, *Arterioscler Thromb Vasc Biol* 27(2) (2007) 290-6.

[29] B. Jastrzebska, D. Fotiadis, G.F. Jang, R.E. Stenkamp, A. Engel, K. Palczewski, Functional and structural characterization of rhodopsin oligomers, *J Biol Chem* 281(17) (2006) 11917-22.

[30] A. Cordomi, G. Navarro, M.S. Aymerich, R. Franco, Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins, *Trends Biochem Sci* 40(10) (2015) 548-51.

[31] V. Capra, A. Veltri, C. Foglia, L. Crimaldi, A. Habib, M. Parenti, G.E. Rovati, Mutational analysis of the highly conserved ERY motif of the thromboxane A<sub>2</sub> receptor: alternative role in G protein-coupled receptor signaling, *Mol Pharmacol* 66(4) (2004) 880-9.

[32] M. Ambrosio, F. Fanelli, S. Brocchetti, F. Raimondi, M. Mauri, G.E. Rovati, V. Capra, Superactive mutants of thromboxane prostanoid receptor: functional and computational analysis of an active form alternative to constitutively active mutants, *Cell Mol Life Sci* 67(17) (2010) 2979-89.

- [33] G.E. Rovati, Ligand-binding studies: old beliefs and new strategies, *Trends Pharmacol Sci* 19(9) (1998) 365-9.
- [34] V. Capra, M. Busnelli, A. Perenna, M. Ambrosio, M.R. Accomazzo, C. Gales, B. Chini, G.E. Rovati, Full and partial agonists of thromboxane prostanoid receptor unveil fine tuning of receptor superactive conformation and G protein activation, *PloS one* 8(3) (2013) e60475.
- [35] P. Konig, G. Krasteva, C. Tag, I.R. Konig, C. Arens, W. Kummer, FRET-CLSM and double-labeling indirect immunofluorescence to detect close association of proteins in tissue sections, *Lab Invest* 86(8) (2006) 853-64.
- [36] P.J. Munson, D. Rodbard, LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems, *Anal. Biochem.* 107 (1980) 220-239.
- [37] A. De Lean, P.J. Munson, D. Rodbard, Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves, *Am. J. Physiol.* 235 (1978) E97-E102.
- [38] A. Hedberg, S.E. Hall, M.L. Ogletree, D.N. Harris, E.C.-K. Liu, Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A<sub>2</sub>/prostaglandin H<sub>2</sub> receptor in human platelets, *Journal of Pharmacology and Experimental Therapeutics* 245 (1988) 786-792.
- [39] B. Jastrzebska, Y. Chen, T. Orban, H. Jin, L. Hofmann, K. Palczewski, Disruption of Rhodopsin Dimerization with Synthetic Peptides Targeting an Interaction Interface, *J Biol Chem* 290(42) (2015) 25728-44.
- [40] S. Bulenger, S. Marullo, M. Bouvier, Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation, *Trends Pharmacol Sci* 26(3) (2005) 131-7.
- [41] G. Milligan, The role of dimerisation in the cellular trafficking of G-protein-coupled receptors, *Curr Opin Pharmacol* 10(1) (2010) 23-9.

- [42] S.C. Prinster, C. Hague, R.A. Hall, Heterodimerization of G protein-coupled receptors: specificity and functional significance, *Pharmacol Rev* 57(3) (2005) 289-98.
- [43] G. Milligan, G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function, *Br J Pharmacol* 158(1) (2009) 5-14.
- [44] N.J. Smith, G. Milligan, Allosterity at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes, *Pharmacol Rev* 62(4) (2010) 701-25.
- [45] M. Neri, S. Vanni, I. Tavernelli, U. Rothlisberger, Role of aggregation in rhodopsin signal transduction, *Biochemistry* 49(23) (2010) 4827-32.
- [46] L.P. Pellissier, G. Barthet, F. Gaven, E. Cassier, E. Trinquet, J.P. Pin, P. Marin, A. Dumuis, J. Bockaert, J.L. Baneres, S. Claeysen, G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient, *J Biol Chem* 286(12) (2011) 9985-97.
- [47] K.G. Harikumar, D. Wootten, D.I. Pinon, C. Koole, A.M. Ball, S.G. Furness, B. Graham, M. Dong, A. Christopoulos, L.J. Miller, P.M. Sexton, Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allosterity, *Proc Natl Acad Sci U S A* 109(45) (2012) 18607-12.
- [48] J.L. Baneres, J. Parello, Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein, *J Mol Biol* 329(4) (2003) 815-29.
- [49] S. Filipek, K.A. Krzysko, D. Fotiadis, Y. Liang, D.A. Saperstein, A. Engel, K. Palczewski, A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin interface, *Photochem Photobiol Sci* 3(6) (2004) 628-38.
- [50] K. Herrick-Davis, E. Grinde, T.J. Harrigan, J.E. Mazurkiewicz, Inhibition of serotonin 5-hydroxytryptamine<sub>2c</sub> receptor function through heterodimerization: receptor dimers bind two molecules of ligand and one G-protein, *J Biol Chem* 280(48) (2005) 40144-51.

- [51] B. Jastrzebska, T. Orban, M. Golczak, A. Engel, K. Palczewski, Asymmetry of the rhodopsin dimer in complex with transducin, *Faseb J* 27(4) (2013) 1572-84.
- [52] W.M. Oldham, H.E. Hamm, Structural basis of function in heterotrimeric G proteins, *Q Rev Biophys* 39(2) (2006) 117-66.
- [53] H.E. Hamm, D. Deretic, A. Arendt, P.A. Hargrave, B. Koenig, K.P. Hofmann, Site of G protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit, *Science* 241(4867) (1988) 832-5.
- [54] R. Herrmann, M. Heck, P. Henklein, K.P. Hofmann, O.P. Ernst, Signal transfer from GPCRs to G proteins: role of the G alpha N-terminal region in rhodopsin-transducin coupling, *J Biol Chem* 281(40) (2006) 30234-41.
- [55] J.M. Taylor, G.G. Jacob-Mosier, R.G. Lawton, A.E. Remmers, R.R. Neubig, Binding of an alpha 2 adrenergic receptor third intracellular loop peptide to G beta and the amino terminus of G alpha, *J Biol Chem* 269(44) (1994) 27618-24.
- [56] O.G. Kisselev, M.A. Downs, Rhodopsin-interacting surface of the transducin gamma subunit, *Biochemistry* 45(31) (2006) 9386-92.
- [57] P. Scheerer, J.H. Park, P.W. Hildebrand, Y.J. Kim, N. Krauss, H.W. Choe, K.P. Hofmann, O.P. Ernst, Crystal structure of opsin in its G-protein-interacting conformation, *Nature* 455(7212) (2008) 497-502.
- [58] S.G. Rasmussen, B.T. DeVree, Y. Zou, A.C. Kruse, K.Y. Chung, T.S. Kobilka, F.S. Thian, P.S. Chae, E. Pardon, D. Calinski, J.M. Mathiesen, S.T. Shah, J.A. Lyons, M. Caffrey, S.H. Gellman, J. Steyaert, G. Skiniotis, W.I. Weis, R.K. Sunahara, B.K. Kobilka, Crystal structure of the beta2 adrenergic receptor-Gs protein complex, *Nature* 477(7366) (2011) 549-55.

- [59] S. Angers, A. Salahpour, E. Joly, S. Hilairret, D. Chelsky, M. Dennis, M. Bouvier, Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET), *Proc Natl Acad Sci U S A* 97(7) (2000) 3684-9.
- [60] D.G. Lambright, J. Sondek, A. Bohm, N.P. Skiba, H.E. Hamm, P.B. Sigler, The 2.0 Å crystal structure of a heterotrimeric G protein., *Nature* 379(6563) (1996) 311-9.
- [61] C.A. Johnston, D.P. Siderovski, Receptor-mediated activation of heterotrimeric G-proteins: current structural insights, *Mol Pharmacol* 72(2) (2007) 219-30.
- [62] B. Jastrzebska, Y. Tsybovsky, K. Palczewski, Complexes between photoactivated rhodopsin and transducin: progress and questions, *Biochem J* 428(1) (2010) 1-10.
- [63] Y. Hou, I. Azpiazu, A. Smrcka, N. Gautam, Selective role of G protein gamma subunits in receptor interaction, *J Biol Chem* 275(50) (2000) 38961-4.
- [64] J.A. Hern, A.H. Baig, G.I. Mashanov, B. Birdsall, J.E. Corrie, S. Lazareno, J.E. Molloy, N.J. Birdsall, Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules, *Proc Natl Acad Sci U S A* 107(6) (2010) 2693-8.
- [65] D. Calebiro, F. Rieken, J. Wagner, T. Sungkaworn, U. Zabel, A. Borzi, E. Cocucci, A. Zurn, M.J. Lohse, Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization, *Proc Natl Acad Sci U S A* 110(2) (2013) 743-8.

**Table 1.** Binding affinities of [<sup>3</sup>H]SQ29,548 in HEK293 cells transiently expressing the WT or mutant human TP receptors. Binding affinities and capacities were obtained by simultaneous analysis of at least six independent mixed-type experiments, each performed in duplicate (see Materials and Methods).

<b>Receptor</b>	<b>K<sub>d</sub>, nM ± %CV</b>	<b>B<sub>max</sub>, pmol/mg prot ± %CV</b>
WT	6.1 ± 30	0.85 ± 47
DDM	7.6 ± 28	1.3 ± 38

**Table 2.** Total IP dose-response parameters for different agonists in HEK293T cells transiently expressing the WT or DDM receptors. Values of EC<sub>50</sub> and E<sub>max</sub> were obtained by simultaneous analysis with GraphPad Prism of at least three independent experiments each performed in duplicates or triplicates.

	WT		DDM	
Agonist	EC <sub>50</sub> , nM ± %CV	E <sub>max</sub> , fold increase ± %CV	EC <sub>50</sub> , nM ± %CV	E <sub>max</sub> , fold increase ± %CV
U46619	45 ± 31	8.1 ± 4.5	270 ± 23**	7.7 ± 4
I-BOP	17.6 ± 29	7.3 ± 5	110 ± 54**	6.7 ± 12
8-isoPGE <sub>2</sub>	702 ± 82	2.8 ± 14§	5400 ± 85**	2.8 ± 14§
8- isoPGF <sub>2</sub> □	5361 ± 93	2.7 ± 13§	32400 ± 89**	2.7 ± 13§

\*\* p < 0.01 vs. WT

§ shared parameters



**Table 3.** Agonist affinities for the receptor binding site labeled by [<sup>3</sup>H]SQ29,548 in HEK293T cells transiently expressing the WT or the DDM receptors.  $K_{d/i}$  values were obtained by simultaneous analysis of at least three independent experiments analyzed with GraphPad Prism implemented with the LIGAND model (see under Experimental procedures).

	<b>WT</b>	<b>DDM</b>
<b>Agonist</b>	<b><math>K_{d/i}</math>, nM <math>\pm</math> %CV</b>	<b><math>K_{d/i}</math>, nM <math>\pm</math> %CV</b>
U46619	199 $\pm$ 13	404 $\pm$ 24
I-BOP	23 $\pm$ 30	37 $\pm$ 30
8-isoPGE <sub>2</sub>	4296 $\pm$ 35	2838 $\pm$ 41
8-isoPGF <sub>2</sub> $\alpha$	16900 $\pm$ 38	34360 $\pm$ 64

Table 4. BRET concentration-response parameters for U46619-induced G protein activation in HEK293T cells transiently expressing the WT or different TP $\alpha$  receptor mutants. Values of EC<sub>50</sub>'s and E<sub>max</sub>'s were obtained by simultaneous analysis with GraphPad Prism (see Section 2) of at least three independent experiments each performed in triplicates.

	<b>EC<sub>50</sub>, nM <math>\pm</math> %CV</b>	<b>E<sub>max</sub>, <math>\pm</math> %CV</b>
WT	29.9 $\pm$ 28	-0.12 $\pm$ 4
DDM	161 $\pm$ 36**	-0.095 $\pm$ 5
N42S	94.5 $\pm$ 15**	-0.13 $\pm$ 3
W29C	247 $\pm$ 19**	-0.13 $\pm$ 4


\*\*

p < 0.01 vs. WT.

## LEGEND TO THE FIGURES

### FIGURE 1. Predicted dimeric model of TP $\alpha$ .


Representation of the predicted dimeric interface of TP $\alpha$  seen from the intracellular side in a direction parallel to the membrane surface. For the sake of clarity only TM1 is shown. The side chains of the TM1 interface amino acids subjected to alanine substitutions are shown in gray.



### FIGURE 2. [<sup>3</sup>H]SQ29,548 binding curves of of TP $\alpha$ WT and TP $\alpha$ DDM and mutant surface expression in HEK293T cells.

Panel A. [<sup>3</sup>H]SQ29,548 binding studies in HEK293T cells transiently expressing the WT (■) or DDM (●) of human TP $\alpha$  receptor. Mixed type curves were performed at 25°C with 30 min incubation. Binding is expressed as the ratio of bound ligand to total ligand concentrations (B/T, dimensionless) versus the logarithm of total unlabeled ligand concentration (Log T). Non-specific binding was calculated by computer as one of the unknown parameters of the model and was always <10% of total binding. Curves are


computer generated from the simultaneous analysis of at least six experiments, each in duplicate. Values for  $K_{d/i}$  are shown in Table 1. Panel B. Representative images of fluorescent signals emitted by donor (500 ng DNA HA-TP□DDM; green) and acceptor (500 ng DNA Myc- TP□DDM red) fluorochromes in two contiguous HEK293T cells expressing TP□ DDM mutant.



**FIGURE 3. Western blotting and acceptor photobleaching FRET analysis of HEK-293T cell transiently transfected with either TP□□WT or DDM mutant.**


Panel A shows one representative analysis of eight independent western blots. Histograms in Panel B show the densitometric analysis of bands referred to mono- and dimeric Myc-tagged WT and DDM mutant receptors performed with ‘gel analyzer’ ImageJ’ plugin. The results are expressed as relative over total intensities of each single lane. Comparison of multiple groups performed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test reveals a statistically significant decrease in the dimeric and an increase in the monomeric form of DDM compared to TP□□WT (\*\*p<0.001). Error bars represent the means ± SE of

at least three independent experiments. Panel C and D. HEK293T cells co-transfected with TP□□WT or DDM mutant, tagged with two different epitopes□□were labeled *in vivo* with the corresponding anti-tag antibodies. After fixation cells were subjected to indirect immunofluorescence with Alexa Fluor 488- (donor fluorochrome) or 555 (acceptor fluorochrome)-conjugated secondary antibodies and imaged with laser scanning confocal microscopy. Panel C show representative images of fluorescent signals emitted by donor (2.5 ng DNA HA-TP□□green□□and acceptor□□2.5 ng DNA Myc-TP□□red□□fluorochromes in two contiguous HEK293T cells expressing WT HA-TP□□and Myc-TP□□pairs before and after laser-induced photobleaching of acceptor fluorescence in a defined plasma membrane region of interest (ROI; dotted line). Panel D show the quantitation of average percent donor and acceptor fluorescence intensities of WT and DDM mutant HA-TP□ and Myc-TP□, respectively, normalized for unbleached ‘sentinel’ plasma membrane ROIs (broken lines in panel A). No statistically significant differences were observed in acceptor recovery (i.e. FRET signal) comparing the three different levels of expression transfected (● 500 ng, ■ 5 ng, ▲ 0.5 ng cDNA). The decrease in WT and DDM Myc-TP□□acceptor signals are not significantly different. Statistical analysis of immunofluorescence data was performed using one-way ANOVA repeated measurements with one grouping factor for all frames. Data are expressed as the means ± SE of 10 different fields from three independent experiments. Scale bar = 10□m.




**FIGURE 4. Basal activity in HEK293T cells transiently expressing TP $\alpha$  WT or DDM mutants in the absence and presence of G $\alpha$ q overexpression.**

Total IP accumulation in basal conditions (white bars) and in the presence (black bars) of G $\alpha$ q overexpression (TP $\alpha$  and G $\alpha$ q plasmids were added in a 1:5 ratio (5xGq). Data are expressed as dpm/well. Error bars represent the means  $\pm$  SE of at least three independent experiments each performed in duplicates or triplicates.



**FIGURE 5. IP dose-response curves in HEK293T cells transiently expressing equal amounts of the WT (A and C) or DDM (B and D) of human TP $\alpha$  receptor.**


Panel A. Agonist-induced total IP accumulation in HEK293T cells was measured after incubation in the absence (basal) or presence of increasing concentrations of the indicated agonists for 30 min. Panel A and B. Agonist-induced effects (■ U46619, ○ I-BOP, ● 8-isoPGE<sub>2</sub>, △ 8-iso-PGF<sub>2</sub>α). Panels C and D. Antagonist induced-effects (■ SQ29,548, ○ Ramatroban). Data are expressed as fold increase over basal. Curves are computer-generated from the simultaneous analysis of at least three independent experiments each performed in duplicates or triplicates. Error bars represent the means ± SE. Values for EC<sub>50</sub>s and significant differences from WT are shown in Table 2.



**FIGURE 6. IP dose-response curves (A) and acceptor photobleaching FRET analysis (B) of HEK293T transiently expressing WT, DDM or TPtrunc of human TP $\alpha$  receptor.**

Panel A. Agonist-induced total IP accumulation was measured after incubation in the presence of increasing concentrations of U46619 in HEK293T cells transfected with (■) TP $\alpha$  WT, (□) DDM, (●) TP $\alpha$  WT + TPtrunc, (○) TP $\alpha$  WT + TPtrunc TM1 and (△) TPtrunc alone. TPtrunc TM1 represents the truncated form of TP carrying the same eight mutations as DDM. Data are expressed as fold increase over basal. Curves are computer-generated from the simultaneous analysis of at least three independent experiments each performed in duplicates or triplicates. Error bars represent the means  $\pm$  SE. Panel B. The graph shows the quantitation of average percent donor and acceptor fluorescence intensities in HEK293T transfected with TP $\alpha$  couples (■ WT/WT, ▲ WT/DDM and ● WT/TPtrunc respectively) with a 1:1 DNA ratio, normalized for unbleached ‘sentinel’ plasma membrane ROIs in acceptor photobleaching FRET assays. No statistically significant differences were

observed in acceptor recovery (i.e. FRET signal) comparing the WT/WT and WT/TPtrunc samples while, as previously observed, WT/DDM couple do not show any significant FRET signals. Statistical analysis data was performed using one-way ANOVA repeated measurements with one grouping factor for all frames. Data are expressed as the means  $\pm$  SE of 10 different fields from three independent experiments.




**FIGURE 7. Ligand binding profile of WT and DDM of human TP $\alpha$  receptor**

Agonist binding studies in HEK293T cells transiently expressing the WT (A and C) or DDM (B and D) of human TP $\alpha$  receptor. For each construct, cold SQ29,548(■), U46619(□), I-BOP(○), 8-isoPGE<sub>2</sub>(●) or 8-isoPGF<sub>2</sub>□□△) or PTA2(▲) were used in competition against 1 nM [<sup>3</sup>H]SQ29,54. Mixed type curves and heterologous competition curves were performed at 25°C with 30 min incubation. Binding is expressed as the ratio of bound ligand to total ligand concentrations (B/T, dimensionless) versus the logarithm of total unlabeled ligand concentration (Log T). Non-specific binding was calculated by computer as one of the




unknown parameters of the model and was always <10% of total binding. Curves are computer generated from the simultaneous analysis of at least three independent mixed-type and heterologous competition experiments, each in duplicate. Values for  $K_{d/i}$  are shown in Table 2.



**FIGURE 8. TP $\alpha$  receptor expression in human platelets.**

Total TP receptor expression was assessed in platelets from healthy donors (HD) or a patient expressing the W29C-TP $\alpha$  (W29C) variant by immunoblotting with a receptor specific antibody. Panel A. Representative blot of four independent experiments. Equal loading was confirmed by assessing tubulin levels (lower blot). Panel B. Densitometric analysis of bands referred to as monomer, dimer and oligomer as assessed using ImageJ software. Data are expressed as band density (band density - background). Comparison of multiple groups performed using one-way ANOVA followed by Bonferroni's Multiple Comparison Test.



**FIGURE 9. Acceptor photobleaching FRET analysis of HEK293T cells transiently expressing WT-WT, WT-W29C or WT-N42S HA- and FLAG-tagged TP $\alpha$  pairs and IP dose-response curves for W29C receptor variant**

Panel A and B. HEK293T cells co-transfected with different TP $\alpha$  pairs, tagged with HA and FLAG epitopes, were *in vivo* labeled with the corresponding anti-tag antibodies. After fixation, cells were subjected to indirect immunofluorescence with Alexa Fluor 488- (donor fluorochrome) or 555 (acceptor fluorochrome)-conjugated secondary antibodies and imaged with laser scanning confocal microscopy. Panel A shows representative images of fluorescent signals emitted by donor (green) and acceptor (red) fluorochromes in two contiguous HEK293T cells expressing WT FLAG-TP $\alpha$  and HA-TP $\alpha$  pair before and after laser-induced photobleaching of acceptor fluorescence in a defined plasma membrane region of interest (ROI; dotted line). Panel B shows the histogram of the quantitation of average percent donor fluorescence intensities of WT-WT, WT-N42S or WT-W29C TP $\alpha$  pairs, normalized for

unbleached 'sentinel' plasma membrane ROIs after laser-induced photobleaching of acceptor fluorescence. Statistical analysis of immunofluorescence data was performed using one-way ANOVA repeated measurements with one grouping factor (\*\* $p < 0.01$ ;  $n=40$ , 4 independent experiments). Data are expressed as the means  $\pm$  SE of ten different fields from four independent experiments. Scale bar: 10  $\mu$ m. Panel C. Agonist-induced total IP accumulation in HEK293T cells was measured after incubation in the absence (basal) or presence of increasing concentrations of the indicated agonists for 30 min ( $\square$  U46619,  $\circ$  I-BOP,  $\bullet$  8-isoPGE<sub>2</sub>,  $\blacktriangle$  8-iso-PGF<sub>2</sub> $\alpha$ ). Data are expressed as fold increase over basal. Curves are computer-generated from the simultaneous analysis of at least three independent experiments each performed in duplicates or triplicates. Error bars represent the means  $\pm$  SE.





Fig. 10. IP dose-response curves in HEK293T cells transiently expressing equal amounts of the WT, W29C or N42S mutants of human TP $\alpha$  receptor. Agonist-induced total IP accumulation in HEK293T cells was measured after incubation in the absence (basal) or presence of increasing concentrations of the indicated agonists for 30 min (Panel A ■, □ U46619, ●, ○ I-BOP; Panel B ◆, ◇ 8-isoPGE<sub>2</sub>, ▲, △ 8-iso-PGF<sub>2</sub> $\alpha$ ). Data are expressed as fold increase over basal. Curves are computer-generated from the simultaneous analysis of at least three independent experiments each performed in duplicates or triplicates. Error bars represent the means  $\pm$  SE.




Fig. 11. BRET<sup>2</sup> measurement of G $\alpha_q$  $\beta_1\gamma_2$  complex activation in HEK293T cells expressing equal amounts of WT, DDM, W29C or N42S mutants of human TP $\alpha$  receptor. A and B. BRET was measured in HEK293T cells co-expressing G $\alpha_q$ -Rluc8 together with GFP<sup>10</sup>-G $\gamma_2$  and G $\beta_1$  in the presence of WT (■), DDM (□) N42S (△) or W29C (▽) mutants of the human TP $\alpha$  receptor and stimulated with increasing concentrations of U46619 for 2 min. Results are indicated as BRET ligand effect that has been calculated as the differences in the

BRET signal measured in the presence and the absence of the agonist, and are expressed as the mean value  $\pm$  SE of at least three independent determinations. Values for  $EC_{50}$ 's and significant differences from WT are shown in Table 4.

